Literature DB >> 14529950

Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models.

Matthew E Barton1, Steven C Peters, Harlan E Shannon.   

Abstract

Glutamatergic ionotropic and metabotropic receptor modulators have been shown to produce anticonvulsant activity in a number of animal seizure models, e.g. maximal electroshock (MES) and DBA/2 sensory-induced seizures. The 6 Hz model of partial seizures is an alternative low frequency, long duration stimulation paradigm resulting in a seizure characterized by jaw and forelimb clonus, immobility, and an elevated tail (Straub-tail). A unique aspect of this model is that it is the only acute electrically-induced seizure model in which levetiracetam has displayed anticonvulsant activity, suggesting that the 6 Hz seizure model may be useful in identifying compounds with unique anticonvulsant profiles. The purpose of the present study was to examine the role of glutamate receptors in the MES and 6 Hz seizure models using a number of NMDA, AMPA/KA, and mGlu receptor modulators. The pharmacological profile of the 6 Hz seizure model was compared to that of the MES model using eight ionotropic glutamate receptor antagonists and eight mGlu receptor modulators. The ionotropic receptor antagonists MK-801, LY235959, NBQX, LY293558, GYKI 52466, LY300168, and LY377770 produced complete protection from tonic extension in the MES model. Furthermore, the noncompetitive mGlu1 (LY456236) and mGlu5 (MPEP) metabotropic receptor antagonists and the mGlu8 metabotropic receptor agonist (PPG) were also effective in the MES model whereas the competitive mGlu1 (LY367385) receptor antagonist, the mGlu2/3 (LY379268 and LY389795) and Group III (L-AP4) metabotropic receptor agonists were ineffective. In contrast, all of the compounds tested, produced dose-dependent protection in the 6 Hz model with an increase in potency as compared to the MES model. The largest protective indices (P.I.=TD50/ED50) observed were associated with the iGlu5 antagonist LY382884 and the mGlu2/3 receptor agonists LY379268 and LY389795 (P.I.=>14, 14, and 4.9, respectively) in the 6 Hz model. The results from the present study support the continued search for glutamate receptor modulators as potential antiepileptic agents. Furthermore these results illustrate the importance of using several different animal seizure models in the search for novel AEDs and the potential utility of the 6 Hz seizure model in identifying novel AEDs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14529950     DOI: 10.1016/j.eplepsyres.2003.08.001

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  27 in total

Review 1.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

Review 2.  Discovery of antiepileptic drugs.

Authors:  Misty Smith; Karen S Wilcox; H Steve White
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Development and pharmacologic characterization of the rat 6 Hz model of partial seizures.

Authors:  Cameron S Metcalf; Peter J West; Kyle E Thomson; Sharon F Edwards; Misty D Smith; H Steve White; Karen S Wilcox
Journal:  Epilepsia       Date:  2017-04-27       Impact factor: 5.864

4.  A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors.

Authors:  Hyekyung P Cho; Darren W Engers; Daryl F Venable; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Kyle A Emmitte; Alice L Rodriguez
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

5.  Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands.

Authors:  Linda M Rorick-Kehn; John C Hart; David L McKinzie
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 6.  Ligands for ionotropic glutamate receptors.

Authors:  Geoffrey T Swanson; Ryuichi Sakai
Journal:  Prog Mol Subcell Biol       Date:  2009

7.  Pharmacological Preconditioning with GYKI 52466: A Prophylactic Approach to Neuroprotection.

Authors:  Chelsea S Goulton; Anna R Patten; John R Kerr; D Steven Kerr
Journal:  Front Neurosci       Date:  2010-08-03       Impact factor: 4.677

8.  Increased sensitivity to kainic acid in a genetic model of reduced NMDA receptor function.

Authors:  Gary E Duncan; Ken Inada; Beverly H Koller; Sheryl S Moy
Journal:  Brain Res       Date:  2009-10-22       Impact factor: 3.252

9.  Effects of subtype-selective group I mGluR antagonists on synchronous activity induced by 4-aminopyridine/CGP 55845 in adult guinea pig hippocampal slices.

Authors:  Alejandro Salah; Katherine L Perkins
Journal:  Neuropharmacology       Date:  2008-04-23       Impact factor: 5.250

10.  Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice.

Authors:  M Foster Olive; Howard C Becker
Journal:  Alcohol       Date:  2008-05       Impact factor: 2.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.